ArticlePoultry science2026
Evaluation of immune protective efficacy of recombinant subunit vaccines based on Eimeria tenella EtAMA1 and EtSAG13.
Article in Poultry science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Avian coccidiosis is a severe parasitic disease caused by infection with species of the genus Eimeria, among which Eimeria tenella (E. tenella) is one of the most pathogenic. This study aimed to evaluate the protective efficacy of recombinant subunit vaccine candidates based on E. tenella apical membrane antigen 1 (EtAMA1) and surface antigen 13 (EtSAG13) against E. tenella infection in chickens. To this end, the EtAMA1 and EtSAG13 genes were cloned, the regions encoding the predicted signal peptides and transmembrane domains were removed, the sequences were optimized, and the resulting fragments were inserted into the pET-28a(+) vector. The recombinant subunit vaccine candidates rEtAMA1, rEtSAG13, and rEtAMA1-SAG13 were successfully constructed, and the corresponding recombinant proteins were expressed. Subsequently, animal experiments were conducted to evaluate the immunoprotective effects of the recombinant proteins at different doses (50 and 100 μg). The results showed that all three recombinant proteins were specifically recognized by sera from chickens infected with E. tenella and by polyclonal antibodies prepared in the laboratory. The group immunized with 50 μg rEtAMA1-SAG13 showed the greatest protective effect, with an anticoccidial index (ACI) of 175.48, indicating moderate anticoccidial efficacy. Histopathological analysis further revealed that cecal lesions were significantly alleviated in the immunized groups. Furthermore, serum levels of specific antibodies (IgG and IgY) and cytokines (IL-2, IL-6, IL-17, and IFN-γ) were significantly higher in the immunized groups than in the unimmunized group (P < 0.05). In conclusion, the recombinant subunit vaccine candidate combining EtAMA1 and EtSAG13 provides effective immune protection against E. tenella infection and holds promise for the prevention and control of chicken coccidiosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.